The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Feb. 3, 11:43 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #23. Mallinckrodt plc Cadence Pharmaceuticals, Inc.

Acquirer: Mallinckrodt plc (MNK)
Acquiree: Cadence Pharmaceuticals, Inc. (CADX)
Details: Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion. As previously disclosed, Mallinckrodt expects that the acquisition will be immediately accretive to its fiscal year 2014 adjusted diluted earnings per share, and significantly accretive to its fiscal year 2015 adjusted diluted earnings per share.

Mallinckrodt develops, manufactures, and markets pharmaceutical products and diagnostic imaging agents. Co. focuses on the manufacturing of pain management medications. Co provides its products to several wholesalers and retail drug store chains.

Open the MNK Page at The Online Investor »

Mallinckrodt develops, manufactures, and markets pharmaceutical products and diagnostic imaging agents. Co. focuses on the manufacturing of pain management medications. Co provides its products to several wholesalers and retail drug store chains.

Open the CADX Page at The Online Investor »

Company Name: 
Mallinckrodt Plc New
Stock buyback: 
MNK buyback
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MNK: 
2
Total Market Value Held by ETFs: 
$3.56M
Company Name: 
Cadence Pharmaceuticals Inc
Website: 
www.cadencepharm.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 23 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2023, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.